Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Share-based Compensation (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Share-based Compensation for 3 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 1.44% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.6 million, a 13.12% increase, with the full-year FY2024 number at $7.4 million, up 50.08% from a year prior.
  • Share-based Compensation was $1.7 million for Q3 2025 at Mereo BioPharma, down from $2.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.3 million in Q1 2025 to a low of $817000.0 in Q4 2023.
  • A 3-year average of $1.7 million and a median of $1.7 million in 2025 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 121.89% in 2024, then decreased 1.44% in 2025.
  • Mereo BioPharma's Share-based Compensation stood at $817000.0 in 2023, then surged by 85.43% to $1.5 million in 2024, then grew by 13.0% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Share-based Compensation are $1.7 million (Q3 2025), $2.1 million (Q2 2025), and $2.3 million (Q1 2025).